Sayaka Mizutani

Sayaka Mizutani

Auto-generated profile, based on publicly available information

Sayaka Mizutani

School of Life Science and Technology, Institute of Science Tokyo, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
SYShinichi Yachida
Shinichi Yachida
SMSayaka Mizutani
Sayaka Mizutani
HSHirotsugu Shiroma
Hirotsugu Shiroma
SSSatoshi Shiba
Satoshi Shiba
TNTakeshi Nakajima
Takeshi Nakajima
TYTakuji Yamada
Takuji Yamada

16 January 2020 in Gut
Verified
Journal Article
Open access
PDF file
PEPande Putu Erawijantari
Pande Putu Erawijantari
SMSayaka Mizutani
Sayaka Mizutani
HSHirotsugu Shiroma
Hirotsugu Shiroma
SSSatoshi Shiba
Satoshi Shiba
TNTakeshi Nakajima
Takeshi Nakajima
TYTakuji Yamada
Takuji Yamada
Objective Recent evidence points to the gut microbiome’s involvement in postoperative outcomes, including after gastrectomy. Here, we investigated the influence of gastrectomy for gastric cancer on the gut microbiome and metabolome, and how it related to postgastrectomy conditions. Design We performed shotgun metagenomics sequencing and capillary electrophoresis time-of-flight mass spectrometry-based metabolomics analyses on faecal samples collected from participants with a history of gastrectomy for gastric cancer (n=50) and compared them with control participants (n=56). Results The gut microbiota in the gastrectomy group showed higher species diversity and richness (p<0.05), together with greater abundance of aerobes, facultative anaerobes and oral microbes. Moreover, bile acids such as genotoxic deoxycholic acid and branched-chain amino acids were differentially abundant between the two groups (linear discriminant analysis (LDA) effect size (LEfSe): p<0.05, q2.0), as were also Kyoto Encyclopedia of Genes and Genomes modules involved in nutrient transport and organic compounds biosynthesis (LEfSe: p<0.05, q2.0). Conclusion Our results reveal alterations of gut microbiota after gastrectomy, suggesting its association with postoperative comorbidities. The multi-omic approach applied in this study could complement the follow-up of patients after gastrectomy.

7 January 2020 in Cancer Science
Verified
Journal Article
Open access
PDF file
SMSayaka Mizutani
Sayaka Mizutani
TYTakuji Yamada
Takuji Yamada
SYShinichi Yachida
Shinichi Yachida
Colorectal cancer (CRC) is highly prevalent worldwide. In 2018, there were over 1.8 million new cases. Most sporadic CRC develop from polypoid adenomas and are preceded by intramucosal carcinoma (stage 0), which can progress into more malignant forms. This developmental process is known as the adenoma‐carcinoma sequence. Early detection and endoscopic removal are crucial for CRC management. Accumulating evidence suggests that the gut microbiota is associated with CRC development in humans. Comprehensive characterization of this microbiota is of great importance to assess its potential as a diagnostic marker in the very early stages of CRC. In this review, we summarized recent studies on CRC‐associated bacteria and their carcinogenic mechanisms in animal models, human cell lines and human cohorts. High‐throughput technologies have facilitated the identification of CRC‐associated bacteria in human samples. We have presented our metagenome and metabolome studies on fecal samples collected from a large Japanese cohort that revealed stage‐specific phenotypes of the microbiota in CRC. Furthermore, we have discussed the potential carcinogenic mechanisms of the gut microbiota, from which we can infer whether changes in the gut microbiota are a cause or effect in the multi‐step process of CRC carcinogenesis.

6 December 2022 in Cancer Prevention Research
Verified
Journal Article
Closed access
PDF file
NNNobuhiro Narii
Nobuhiro Narii
LZLing Zha
Ling Zha
TSTomotaka Sobue
Tomotaka Sobue
Tetsuhisa KitamuraTetsuhisa Kitamura
Tetsuhisa Kitamura
SSSatoshi Shiba
Satoshi Shiba
SYShinichi Yachida
Shinichi Yachida
Fusobacterium nucleatum is involved in the development and progression of colorectal cancer. Although the gut microbiota is influenced by diet, studies on the association between diet and F. nucleatum are limited. We aimed to evaluate the association between various dietary factors and fecal F. nucleatum in healthy adults without a history of colorectal cancer or precancerous lesions. This was a cross-sectional study. Subjects who underwent total colonoscopy at the National Cancer Center Hospital (Tokyo, Japan) were included. Healthy subjects (n = 212) were divided into two groups according to the presence or absence of F. nucleatum in their feces which was calculated from data of whole-genome shotgun sequencing, with the group with F. nucleatum serving as cases and the group without F. nucleatum serving as controls. Multivariable logistic regression analysis adjusted potential confounders was conducted to estimate the associations between dietary intake and nutrients estimated by a validated food frequency questionnaire and the presence of F. nucleatum in the feces. There was a significant inverse association between dairy products and the presence of fecal F. nucleatum [high vs. low; OR, 0.41; 95% confidence interval, 0.17–0.95; Ptrend, 0.039]. These results may have important implications for colorectal cancer prevention through nutritional intervention. Prevention Relevance: F. nucleatum is well known as a colorectal cancer–associated bacterium. Dietary habits alter the composition and function of the intestinal microbiota. A high intake of dairy products in healthy adults may reduce F. nucleatum and prevent colorectal cancer.

29 August 2025 in Science Advances
Verified
Journal Article
Open access
SWShun Watanabe
Shun Watanabe
MNMasaaki Nakayama
Masaaki Nakayama
TYTakashi Yokoo
Takashi Yokoo
SSSatoru Sanada
Satoru Sanada
YUYoshifumi Ubara
Yoshifumi Ubara
LILUBI-CKD TRIAL Investigators
LUBI-CKD TRIAL Investigators
Chronic kidney disease (CKD) is a life-threatening condition, and constipation is a progressive risk factor. We evaluated changes in uremic toxins, renal function, and the safety of lubiprostone, a selective chloride channel activator, in patients with CKD. In this phase 2, randomized, double-blind, placebo-controlled trial across nine centers in Japan, 150 patients with stage IIIb–IV CKD received lubiprostone (8 or 16 micrograms) or placebo for 24 weeks. The primary end point was change in indoxyl sulfate levels. Secondary end points included other uremic toxins and renal function markers. Lubiprostone did not alter uremic toxin levels but improved or preserved estimated glomerular filtration rate and its slope in the 16-microgram group. Mild-to-moderate gastrointestinal events occurred in the placebo and 16-microgram groups. Multiomics analysis revealed that lubiprostone modulated the gut microbial agmatine pathway and increased spermidine levels, thereby improving renal mitochondrial function. Lubiprostone is a previously unknown and safe therapeutic option to mitigate renal decline in CKD.

5 April 2002 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
KTKiyosei Takasu
Kiyosei Takasu
SMSayaka Mizutani
Sayaka Mizutani
MIMasataka Ihara
Masataka Ihara